EBIT (Annual)

EBIT: Income before interest and taxes.

Madrigal Pharmaceuticals, Inc. (MDGL) had EBIT of $-300.10M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$958.40M
Net Income	$-288.28M
Cost of Goods Sold	$56.15M
Gross Profit	$902.25M
Operating Expenses	$1.26B
Operating Income	$-300.10M
Non-Operating Income/Expense	$11.81M
Pre-Tax Income	$-288.28M
Normalized Pre-Tax Income	$-288.28M
Income after Taxes	$-288.28M
Income from Continuous Operations	$-288.28M
Consolidated Net Income/Loss	$-288.28M
Normalized Income after Taxes	$-288.28M
EBIT	$-300.10M
EBITDA	$-293.78M
Weighted-Average Shares Outstanding (Basic)	22.43M
Weighted-Average Shares Outstanding (Diluted)	22.43M
Earnings per Share (EPS) (Basic)	$-12.85
Earnings per Share (EPS) (Diluted)	$-12.85
Balance Sheet Financials
Current Assets	$1.25B
Property, Plant, and Equipment	$1.50M
Long-Term Assets	$13.82M
Total Assets	$1.26B
Current Liabilities	$310.29M
Long-Term Debt	$339.88M
Long-Term Liabilities	$346.61M
Total Liabilities	$656.90M
Common Equity	$602.69M
Tangible Shareholders Equity	$595.31M
Shareholders Equity	$602.69M
Common Shares Outstanding	22.84M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-189.55M
Cash Flow from Investing Activities	$32.32M
Cash Flow from Financial Activities	$255.98M
Beginning Cash	$105.02M
End Cash	$203.78M
Increase/Decrease in Cash	$98.76M
Stock-Based Compensation	$98.13M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.01
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.36
Debt to Equity Ratio	0.56
Gross Margin	94.14%
Operating Margin	-31.31%
EBIT Margin	-31.31%
EBITDA Margin	-30.65%
Pre-Tax Profit Margin	-30.08%
Profit Margin	-30.08%
Free Cash Flow	$-190.02M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.76
Inventory Turnover	0.75
Receiveable Turnover	7.13
Days Sales in Receivables	51.21
Return on Equity	-47.83%
Return on Tangible Equity	-48.43%
Return on Assets	-22.89%
Return on Investments	-30.58%
Book Value Per Share	$26.39
Free Cash Flow per Share	$-8.47
Operating Cash Flow per Share	$-8.45

Data from Zacks Investment Research, Inc.